科伦博泰生物：芦康沙妥珠单抗的新增适应症上市申请获国家药监局受理

人民财讯2025-05-22

科伦博泰生物在港交所公告，公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗（sac-TMT）（佳泰莱®）的一项新增适应症上市申请已获国家药监局(NMPA)药品审评中心(CDE)受理，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性（HER2-）乳腺癌(BC)成人患者。该申请...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537968500?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-22 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537968500","market":"hk","top_or_hot":-1,"title":"科伦博泰生物：芦康沙妥珠单抗的新增适应症上市申请获国家药监局受理","media":"人民财讯","content":"<div>\n<p>科伦博泰生物在港交所公告，公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗（sac-TMT）（佳泰莱®）的一项新增适应症上市申请已获国家药监局(NMPA)药品审评中心(CDE)受理，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性（HER2-）乳腺癌(BC)成人患者。该申请...</p>\n\n<a href=\"http://hk.eastmoney.com/a/202505223411334219.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦博泰生物：芦康沙妥珠单抗的新增适应症上市申请获国家药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦博泰生物：芦康沙妥珠单抗的新增适应症上市申请获国家药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-22 08:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://hk.eastmoney.com/a/202505223411334219.html><strong>人民财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>科伦博泰生物在港交所公告，公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗（sac-TMT）（佳泰莱®）的一项新增适应症上市申请已获国家药监局(NMPA)药品审评中心(CDE)受理，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性（HER2-）乳腺癌(BC)成人患者。该申请...</p>\n\n<a href=\"http://hk.eastmoney.com/a/202505223411334219.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDE","symbol_name":"科尔黛伦矿业","start_time":0,"source_url":"http://hk.eastmoney.com/a/202505223411334219.html","article_id":"2537968500","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537968500","pubTimestamp":1747872778,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"【科伦博泰生物：芦康沙妥珠单抗的新增适应症上市申请获国家药监局受理】科伦博泰生物在港交所公告，公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗（sac-TMT）（佳泰莱）的一项新增适应症上市申请已获国家药监局(NMPA)药品审评中心(CDE)受理，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性（HER2-）乳腺癌(BC)成人患者。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CDE":"科尔黛伦矿业","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","BK4017":"黄金","BK4190":"消闲用品","ADC":"艾格里房产","BC":"宾士域"},"translate_title":"Kelun Botai Biotech: The application for new indications of Lukang Sartuzumab was accepted by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDE":1,"ADC":1,"BC":1},"content_text":"科伦博泰生物在港交所公告，公司靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗（sac-TMT）（佳泰莱®）的一项新增适应症上市申请已获国家药监局(NMPA)药品审评中心(CDE)受理，用于治疗既往接受过内分泌治疗且在晚期或转移性阶段接受过其他系统治疗的不可切除的局部晚期或转移性激素受体阳性(HR+)且人表皮生长因子受体2阴性（HER2-）乳腺癌(BC)成人患者。该申请是芦康沙妥珠单抗获NMPA受理的第四个适应症上市申请。 （文章来源：人民财讯）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537968500","isCrawlerRequest":true}